Plasma drug activity in patients on treatment for multidrug-resistant tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 2, 2014, Pages 782-788

  Mpagama, Stellah G ^a,b   Ndusilo, Norah ^b   Stroup, Suzanne ^c   Kumburu, Happiness ^b   Peloquin, Charles A ^d   Gratz, Jean ^c   Houpt, Eric R ^c   Kibiki, Gibson S ^b   Heysell, Scott K ^c  

^a Kibong'Oto National Tuberculosis Hospital   (Tanzania)

^b KILIMANJARO CHRISTIAN MEDICAL CENTRE   (Tanzania)

^c UNIVERSITY OF VIRGINIA   (United States)

^d UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; CYCLOSERINE; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; KANAMYCIN; LEVOFLOXACIN; MOXIFLOXACIN; OFLOXACIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

ADULT; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANT TUBERCULOSIS; PRIORITY JOURNAL; SPUTUM CULTURE; TANZANIA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AMIKACIN; ANTITUBERCULAR AGENTS; CYCLOSERINE; ETHIONAMIDE; FEMALE; FLUOROQUINOLONES; HUMANS; KANAMYCIN; LEVOFLOXACIN; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; OFLOXACIN; PYRAZINAMIDE; SPUTUM; TANZANIA; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY;

EID: 84893469977     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01549-13     Document Type: Article

References (28)

1. Shenoi S, Heysell S, Moll A, Friedland G. 2009. Multidrug-resistant and extensively drug-resistant tuberculosis: consequences for the global HIV community. Curr. Opin. Infect. Dis. 22:11-17. http://dx.doi.org/10.1097/QCO. 0b013e3283210020.
2. Zhang M, Li SY, Rosenthal IM, Almeida DV, Ahmad Z, Converse PJ, Peloquin CA, Neurmberger EL, Grosset JH. 2011. Treatment of tuberculosis with rifamycin containing regimens in immune-deficient mice. Am. J. Respir. Crit. Care Med. 183:1254-1261. http://dx.doi.org/10.1164/rccm.201012-1949OC.
3. Chang KC, Leung CC, Yew WW, Chan SL, Tam CM. 2006. Dosing schedules of 6-month regimens and relapse for pulmonary tuberculosis. Am. J. Respir. Crit. Care Med. 174:1153-1158. http://dx.doi.org/10.1164/rccm.200605-637OC.
4. Egelund EF, Peloquin CA. 2012. Pharmacokinetic variability and tuberculosis treatment outcomes, including acquired drug resistance. Clin. Infect. Dis. 55:178-179. http://dx.doi.org/10.1093/cid/cis366.
5. Heysell SK, Mtabho C, Mpagama SG, Mwaigwisya S, Ndusilo N, Pholwat S, Gratz J, Aarnouste R, Kibiki GS, Houpt ER. 2011. Plasma drug activity assay for treatment optimization in tuberculosis patients. Antimicrob. Agents Chemother. 55:5819-5825. http://dx.doi.org/10.1128/AAC.05561-11.
6. Schlichter JG, MacLean H, Milzer A. 1949. Effective penicillin therapy in subacute bacterial endocarditis and other chronic infections. Am. J. Med. Sci. 217:600-608. http://dx.doi.org/10.1097/00000441-194906000-00002.
7. Reller LB, Stratton CW. 1977. Serum dilution test for bactericidal activity. II. Standardization and correlation with antimicrobial assays and susceptibility tests. J. Infect. Dis. 136:196-204.
8. Wallis RS, Palaci M, Vinhas S, Hise AG, Ribeiro FC, Landen K, Cheon SH, Song HY, Phillips M, Dietx R, Ellner JJ. 2001. A whole blood bactericidal assay for tuberculosis. J. Infect. Dis. 183:1300-1303. http://dx.doi.org/10.1086/ 319679.
9. Ministry of Health of Tanzania. 2009. Health sector strategic plan III (2009-2015). Ministry of Health of Tanzania, Dodoma, Tanzania.
10. Mpagama S, Heysell SK, Ndusilo ND, Kumburu HH, Lekule IA, Kisonga RM, Gratz J, Boeree MJ, Houpt ER, Kibiki GS. 2013. Diagnosis and interim treatment outcomes from the first cohort of multidrugresistant tuberculosis patients in Tanzania. PLoS One 8:e62034. http://dx.doi.org/10.1371/journal.pone.0062034.
11. Hall L, Jude KP, Clark SL, Dionne K, Merson R, Boyer A, Parrish NM, Wengenack NL. 2012. Evaluation of the Sensititre MYCOTB plate for the susceptibility testing of Mycobacterium tuberculosis complex against first and second line agents. J. Clin. Microbiol. 50:3722-3724. http://dx.doi.org/10.1128/ JCM.02038-12.
12. Scarporo C, Ricordio P, Rugerio G, Piccoli P. 2004. Evaluation of the fully automated BACTEC MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide, streptomycin, isoniazid, rifampin, and ethambutol and comparison with the radiometric BACTEC 460TB method. J. Clin. Microbiol. 42:1109-1114. http://dx.doi.org/10.1128/JCM.42.3.1109-1114.2004.
13. Peloquin CA. 2002. Therapeutic drug monitoring in the treatment of tuberculosis. Drugs 62:2169-2183. http://dx.doi.org/10.2165/00003495-200262150- 00001.
14. Chideya S, Winston CA, Peloquin CA, Bradford WZ, Hopewell PC, Wells CD. 2009. Isoniazid, rifampin, ethambutol, and pyrazinamide pharmacokinetics and treatment outcomes among predominantly HIVinfected cohort of adults with tuberculosis from Botswana. Clin. Infect. Dis. 48:1685-1694. http://dx.doi.org/10.1086/599040.
15. Burhan E, Ruesen C, Ruslami R, Ginanjar A, Manngunnegoro H, Ascobat P, Donders R, van Crevel R, Aaronoutse R. 2013. Isoniazid, rifampin, and pyrazinamide plasma concentrations in relation to treatment response in Indonesian pulmonary tuberculosis patients. Antimicrob. Agents Chemother. 57:3614-3619. http://dx.doi.org/10.1128/AAC.02468-12.
16. Espinal M, Farmer P. 2009. The Cambridge Declaration: toward clinical trials for drug-resistant tuberculosis. Int. J. Tuberc. Lung Dis. 13:1-2.
17. Gandhi NR, Nunn P, Dheda K, Schaff HS, Zignol M, van Soolingen Jensen P, Bayona J. 2010. Multidrug-resistant and extensively drugresistant tuberculosis: a threat to global control of tuberculosis. Lancet 375:1830-1843. http://dx.doi.org/10.1016/S0140-6736(10)60410-2.
18. Chigutsa E, Meredith S, Wiesner L, Padayatchi N, Harding J, Moodley P, Mac Kenzie WR, McIlleron H, Kirkpatrick CM. 2012. Population pharmacokinetics and pharmacodynamics of ofloxacin in south African patients with multidrug-resistant tuberculosis. Antimicrob. Agents Chemother. 56:3857-3863. http://dx.doi.org/10.1128/AAC.00048-12.
19. Jacobson KR, Tierny B, Jeon CY, Mitnick CD, Murray MB. 2010. Treatment outcomes among patients with extensively drug-resistant tuberculosis: systematic review and meta-analysis. Clin. Infect. Dis. 51:6-14. http://dx.doi.org/10. 1086/653115.
20. van Deun A, Maug AKJ, Salim MAH, Das PK, Sarker MR, Daru P, Rieder HL. 2010. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am. J. Respir. Crit. Care Med. 182:684-692. http://dx.doi.org/10.1164/rccm.201001-0077OC.
21. Johnson JL, Hadad DJ, Boom WH, Daley CL, Peloquin CA, Eisenach KD, Jankus DD, Debanne SM, Charlebois ED, Maciel E, Palaci M, Dietze R. 2006. Early and extended early bactericidal activity of levofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int. J. Tuberc. Lung Dis. 10:605-612.
22. Peloquin CA, Hadad DJ, Molino LPD, Palaci M, Bloom WH, Dietze R, Johnson JL. 2008. Population pharmacokinetics of levofloxacin, gatifloxacin, and moxifloxacin in adults with pulmonary tuberculosis. Antimicrob. Agents Chemother. 52:852-857. http://dx.doi.org/10.1128/AAC.01036-07.
23. Heiffets L. 1988. Qualitative and quantitative drug-susceptibility tests in mycobacteriology. Am. Rev. Respir. Dis. 137:1217-1222. http://dx.doi.org/10. 1164/ajrccm/137.5.1217.
24. Pasipanodya JG, Gumbo T. 2011. A new evolutionary and pharmacokinetic-pharmacodynamic scenario for rapid emergence of resistance to single and multiple anti-tuberculosis drugs. Curr. Opin. Pharm. 11:1-7. http://dx.doi.org/10.1016/j.coph.2011.03.001.
25. Cox H, Ford N. 2013. Decentralisation of multidrug-resistanttuberculosis care and management. Lancet Infect. Dis. 8:644-646.
26. Wallis RS, Jakubiec WM, Kumar V, Slivia AM, Paige D, Dimitrova D, Li X, Ladutko L, Campbell S, Friedland G, Mitton-Fry M, Miller PF. 2010. Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers. J. Infect. Dis. 202:745-751. http://dx.doi.org/10.1086/655471.
27. Heysell SK, Moore JL, Keller S, Houpt ER. 2010. Therapeutic drug monitoring for slow response to tuberculosis therapy in a state control program; Virginia, U.S.A. Emerg. Infect. Dis. 16:1546-1553. http://dx.doi.org/10.3201/ eid1610.100374.
28. Holland DP, Hamilton CD, Weintrob AC, Engemann JJ, Fortenberry ER, Peloquin CA, Stout JE. 2009. Therapeutic drug monitoring of antimycobacterial drugs in patients with both tuberculosis and advanced human immunodeficiency virus infection. Pharmacotherapy 29:503-510. http://dx.doi.org/10.1592/phco.29. 5.503.